What is the recommended Capizzi‑type interim‑maintenance regimen (vincristine, escalating methotrexate, asparaginase, and intrathecal prophylaxis) for children with acute lymphoblastic leukaemia after induction and consolidation?

Capizzi Protocol Administration in Pediatric Acute Lymphoblastic Leukemia

The Capizzi-type interim maintenance regimen consists of escalating-dose intravenous methotrexate (starting at 100 mg/m² and increasing by 50 mg/m² every 10 days up to a maximum of 300 mg/m²) given without leucovorin rescue, combined with weekly vincristine 1.5 mg/m² (maximum 2 mg), intrathecal methotrexate for CNS prophylaxis, and PEG-asparaginase 2,500 units/m² every 2 weeks, administered during the interim maintenance phases after consolidation. 1

Core Components of the Capizzi Regimen

Interim Maintenance Phase (8 weeks duration)

Methotrexate Escalation Schedule:

• Administer intravenous methotrexate starting at 100 mg/m² on week 1 1
• Increase by 50 mg/m² increments every 10 days (weeks 2,4,6,8) 1
• Maximum dose reaches 300 mg/m² by week 8 1
• Critical distinction: No leucovorin rescue is given with Capizzi methotrexate 2, 3

Vincristine Administration:

• Give 1.5 mg/m² intravenously weekly throughout the 8-week cycle 1
• Cap maximum single dose at 2 mg regardless of body surface area 1

Asparaginase Component:

• Administer PEG-asparaginase 2,500 units/m² intramuscularly every 2 weeks 1
• Alternative: Native E. coli asparaginase 10,000 units/m² can be given on days 3,6,9,12,15, and 18 if PEG formulation unavailable 1

CNS Prophylaxis:

• Give intrathecal methotrexate on weeks 1 and 3 of each interim maintenance cycle 1
• Age-based dosing: 8 mg for age <1 year, 10 mg for 1-2 years, 12 mg for 2-3 years, 15 mg for ≥3 years 1

Treatment Sequence and Timing

The Capizzi regimen is administered during two separate interim maintenance phases in the overall treatment protocol 1:

• Interim Maintenance #1: Begins after completion of Consolidation I (typically 8-12 weeks post-induction) 1
• Delayed Intensification #1: Follows interim maintenance #1 (4 weeks) 1
• Interim Maintenance #2: Administered after delayed intensification #1, using identical dosing to interim maintenance #1 1
• Delayed Intensification #2: For high-risk patients only 1

Critical Safety Monitoring

Baseline Requirements Before Each Methotrexate Dose

Laboratory monitoring must include 2, 3:

• Complete blood count with differential (ANC must be >750/μL to proceed safely) 2
• Comprehensive metabolic panel including ALT, AST, creatinine, and bilirubin 2, 3
• Ensure adequate hydration status clinically 2

Hepatotoxicity Management Algorithm

ALT <2× upper limit of normal (ULN):

• Proceed with scheduled methotrexate dose 4
• Recheck ALT in 7-10 days 4

ALT 2-3× ULN:

• Hold methotrexate until ALT decreases to <2× ULN 4
• Resume at same escalation schedule once resolved 4

ALT >3× ULN:

• Methotrexate is contraindicated; do not administer 4
• Consider leucovorin rescue even without prior methotrexate if severe toxicity develops 3

Permanent discontinuation criteria:

• ALT >20× ULN not resolving to grade <2 within one week 4
• Direct bilirubin >5.0 mg/dL 4

Asparaginase-Specific Precautions

PEG-asparaginase may be given if ALT <3× ULN with enhanced monitoring 4:

• Hold if ALT 2-3× ULN until resolution to <2× ULN 4
• Permanently discontinue for clinical pancreatitis (amylase or lipase >3× ULN persisting >3 days or pseudocyst formation) 4

Toxicity Recognition and Management

Common toxicities with Capizzi methotrexate (occurring in approximately 29% of cycles) 2:

• Febrile neutropenia (most common) 2
• Mucositis (5.5% of cycles, significantly less than high-dose methotrexate at 14.6%) 2
• Thrombocytopenia requiring platelet transfusion 2
• Hepatotoxicity (transaminase elevation) 2, 3

Risk factors for increased toxicity 2:

• Male gender (higher toxicity rates) 2
• Lower baseline absolute neutrophil count 2
• Lower body mass index 2

Severe multiorgan toxicity warning 3:

• Even single intermediate doses can cause pancytopenia, severe dermatologic reactions, and multiorgan failure 3
• Absence of leucovorin rescue increases toxicity risk substantially 3
• Administer high-dose leucovorin (50-100 mg/m² IV every 6 hours) immediately if severe toxicity suspected, even without measurable methotrexate levels 3

Practical Administration Considerations

Drug Sequencing Within Each Cycle

The original Capizzi design intentionally sequences asparaginase after methotrexate to exploit metabolic synergy 5:

• Methotrexate depletes intracellular reduced folates 5
• Subsequent asparaginase blocks protein synthesis, preventing cellular recovery 5
• This sequence enhances antileukemic effect while asparaginase attenuates methotrexate toxicity 5

Avoiding Historical Errors

Do not combine Capizzi methotrexate with other intensive chemotherapy in the same week 6:

• Early protocols combining high-dose methotrexate with teniposide, cytarabine, and asparaginase during induction caused life-threatening gastrointestinal toxicity in 38% of patients, with one death 6
• Allow at least one week for mucosal recovery between intensive chemotherapy cycles 6

Resource-Stratified Modifications

For limited-resource settings where PEG-asparaginase is unavailable 1:

• Substitute native E. coli asparaginase 10,000 units/m² given three times weekly 1
• Maintain the same methotrexate escalation schedule 1
• Ensure intrathecal methotrexate is given on weeks 1 and 3 as minimum CNS prophylaxis 1

Integration with Overall Treatment Protocol

After completing both interim maintenance cycles with Capizzi methotrexate, patients transition to maintenance therapy for 2-2.5 years total from diagnosis 1, 7:

• Daily oral mercaptopurine 37.5-50 mg/m² 1, 7
• Weekly oral methotrexate 15-20 mg/m² 1, 7
• Monthly vincristine 1.5 mg/m² pulses 1, 7
• Dexamethasone 4-6 mg/m² daily for 5 days every 4 weeks 1, 7